search
Back to results

Mitochondrial Function in Patients With Severe Liver Disease (SLDglyc)

Primary Purpose

Hepatic Insufficiency, Hypoalbuminemia

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Orally administered labeled glycerol
Sponsored by
University of Texas Southwestern Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Hepatic Insufficiency

Eligibility Criteria

21 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Severe liver disease defined as known liver disease plus at least one of the following: serum albumin less than 3.0 g/dL or INR more than 2.0.

Exclusion Criteria:

  • Portal systemic encephalopathy
  • Pregnancy or breastfeeding.
  • Anemia (hematocrit < 32%)
  • Significant weight loss or use of diet pills within previous 6 months.
  • Cannot give informed consent, understand the protocol, or tolerate any aspect of the protocol.

Sites / Locations

  • UT Southwestern Medical Center - Advanced Imaging Research Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Orally administered Labeled Glycerol

Arm Description

Patients will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water.

Outcomes

Primary Outcome Measures

Detection of 13C in plasma glucose by NMR of a blood sample
Once at 60 minutes post ingestion and once at 120 minutes ingestion for a total ot 2 times

Secondary Outcome Measures

Full Information

First Posted
April 30, 2015
Last Updated
March 15, 2022
Sponsor
University of Texas Southwestern Medical Center
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT02457702
Brief Title
Mitochondrial Function in Patients With Severe Liver Disease
Acronym
SLDglyc
Official Title
Mitochondrial Function in Patients With Severe Liver Disease
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Terminated
Why Stopped
Unable to recruit. Only 2 subjects completed.
Study Start Date
October 2015 (undefined)
Primary Completion Date
December 2021 (Actual)
Study Completion Date
December 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Texas Southwestern Medical Center
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The researchers will recruit patients with liver disease at Parkland Hospital. Patients will fast overnight, and the next morning will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water. The taste is slightly sweet. Blood will be drawn at 60 min and 120 min after the ingestion. Blood glucose will be isolated and analyzed by NMR. The presence of [5,6-13C2]- and [4,5-13C2]glucose indicates preserved mitochondrial function. The researchers anticipate that patients with severe liver disease will show a decrease in mitochondrial function and will inform biosynthetic function of liver mitochondria. After the first 6 successful exams (see power analysis, below), healthy volunteers (age-, gender-, and race-matched) will be studied at the AIRC and subject to the same protocol.
Detailed Description
The researchers will recruit patients with severe liver disease at Parkland Hospital where the procedure will be performed. Age-, gender- and race-matched healthy subjects will be recruited from general population, and the procedure will be performed at the procedure room of the AIRC. Patients at Parkland will be screened and selected by Dr. Jeffrey Browning and Dr. Rodney Infante. After ingestion of 25 mg/kg [U-13C3]glycerol plus 25 mg/kg unlabeled glycerol in water (total glycerol dose, 50 mg/kg), blood will be drawn at +60 and +120 min. Healthy subjects will make two visits to the AIRC for screening and study procedures. The screening visit will take an hour and the study visit will take 3 hours. Volunteers will be made comfortable in the procedure room of the Research Center. All the study procedures at both Parkland and AIRC will be under the direction of the principal investigator, Dr. Jeffrey Browning.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatic Insufficiency, Hypoalbuminemia

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Orally administered Labeled Glycerol
Arm Type
Experimental
Arm Description
Patients will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water.
Intervention Type
Other
Intervention Name(s)
Orally administered labeled glycerol
Intervention Description
Oral administration of labeled glycerol
Primary Outcome Measure Information:
Title
Detection of 13C in plasma glucose by NMR of a blood sample
Description
Once at 60 minutes post ingestion and once at 120 minutes ingestion for a total ot 2 times
Time Frame
At 60 minutes and 120 minutes post ingestion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Severe liver disease defined as known liver disease plus at least one of the following: serum albumin less than 3.0 g/dL or INR more than 2.0. Exclusion Criteria: Portal systemic encephalopathy Pregnancy or breastfeeding. Anemia (hematocrit < 32%) Significant weight loss or use of diet pills within previous 6 months. Cannot give informed consent, understand the protocol, or tolerate any aspect of the protocol.
Facility Information:
Facility Name
UT Southwestern Medical Center - Advanced Imaging Research Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Mitochondrial Function in Patients With Severe Liver Disease

We'll reach out to this number within 24 hrs